Medicare Part D rebates could drive drug industry from US, PhRMA leader warns
This article was originally published in Scrip
Executive Summary
If Republican leaders in Congress seal a deal with their Democratic colleagues and the White House to apply mandatory Medicaid-style rebates to the Medicare Part D prescription drug programme as part of the ongoing debt ceiling negotiations, the biopharmaceutical industry may decide to pack its bags and say 'zai jian,' 'auf wiedersehen' or even 'hasta la vista, baby' to the US, the head of the pharmaceutical industry's lobbying group warned on 11 July.